ArticleJournal of current ophthalmology
Effect of the Coronavirus Disease 2019 Pandemic on Central Retinal Vein Occlusion.
Article in Journal of current ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To determine the disease prevalence rate and clinical characteristics of central retinal vein occlusion (CRVO) among new patients before and after the declaration of a state of emergency due to coronavirus disease 2019 on April 7, 2020, in Japan. Methods: New patients and patients with newly diagnosed CRVO were categorized into "Before" and "After" groups based on the initial visit. The prevalence rate, sex ratio, and age of patients newly diagnosed with CRVO were compared between the groups. The prevalence rate of patients newly diagnosed with rhegmatogenous retinal detachment (RRD) and pseudoexfoliation glaucoma (PEX) was also examined in the before and after groups. The best-corrected visual acuity (BCVA) at the initial visit, retinal photocoagulation, and BCVA after treatment were compared among 232 eyes observed in 12 ± 2 months after treatment. Results: No significant differences in prevalence rates of CRVO among newly diagnosed patients ( Conclusion: Although the coronavirus disease 2019 pandemic did not affect the prevalence of CRVO among new patients compared with that of RRD and PEX, it may be associated with a greater need for retinal photocoagulation, suggesting changes in disease severity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.